Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02855918
Other study ID # UF 9625
Secondary ID 2015-A01978-41
Status Completed
Phase N/A
First received
Last updated
Start date September 23, 2016
Est. completion date June 24, 2020

Study information

Verified date December 2021
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Suicidal behavior (SB) is a major public health problem in France, with more than 10,000 suicides and 220,000 suicide attempts per year. According to the commonly accepted model for understanding suicidal behavior, individuals who carry a suicidal act when subjected to stress factors (environmental stress, depression, substance ...) are those which have a specific vulnerability. These vulnerabilities can be considered as clinical parameters (propensity to despair, aggressive and/or impulsive traits), neurobiological parameters (dysfunction of the serotonergic system, ...) and cognitive parameters (taking disadvantageous decision ...). Suicidal vulnerability is partly underpinned by genetic factors. The interest of current researches is to identify biomarkers that will improve the opportunities for early identification of subject with a risk for SB. Numerous scientific studies, including post-mortem studies of the brains of suicide completers, have established a link between dysregulation of the ribonucleic acids editing (RNA) of certain genes, the enzymatic activity of Adenosine deaminases acting on RNA (ADARS) responsible for this edition and suicidal behavior. A prospective study is needed to quantify and qualify in the blood of depressed patients (with or without a history of suicide) and healthy controls, the editing changes and the expression and alteration of the activity of ADARS.


Description:

Over two years, 600 participants will be recruited: - 225 subjects with current major depressive episode and an history of suicide attempt (depressed suicide attempters) - 225 subjects with current major depressive episode but with no personal history of suicide attempt (affective controls) - 150 subjects with no history of psychopathology whole life (healthy controls) Each patient will attend a total of 3visits during a follow-up period of 6 months +/- 15 days (inclusion, visit at 3 and 6 months).


Recruitment information / eligibility

Status Completed
Enrollment 600
Est. completion date June 24, 2020
Est. primary completion date June 24, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility No specific inclusion criteria : - 18 to 65 years - Subject who signed the informed consent - Able to understand the nature, purpose and methodology of the study - Able to understand and perform the clinical and neuropsychological evaluations. Specific inclusion criteria depressed suicide attempters: - Subject whose primary psychiatric diagnosis is a major depressive episode according to Diagnostic and Statistical Manual of Mental Disorders -5 (DSM-5) criteria - Personal history of suicide attempt affective controls: - Subject whose primary psychiatric diagnosis is a major depressive episode according to DSM-5 criteria - No personal history of suicide attempt healthy controls: - No personal history of psychiatric disorders (Axis I ) defined by the Mini International Neuropsychiatric Interview (MINI) according to the DSM-5 criteria - No history of suicide attempt Exclusion criteria - Refusal of participation - Deprived of liberty Subject (by judicial or administrative decision) - Subject protected by law (guardianship) - Subject exclusion period in relation to another protocol - Subject is not affiliated to a social security scheme, beneficiary or not such a plan - Subject for which the maximum annual amount of allowances of € 4,500 has been reached - Pregnant women - Breastfeeding Women

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Blood sample for genetic purpose
All the participants will performed the same evaluations and blood analysis : A clinical assessment by psychiatrist Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits… A neuropsychological assessment for the evaluations of cognitive performances A routine blood sampling to the realization of a standard blood test A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript.

Locations

Country Name City State
France University Hospital Montpêllier

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Montpellier Institut National de la Santé Et de la Recherche Médicale, France, Sys2Diag, Mixt laboratory CNRS/Alcediag, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evolution of the modification of the expression of Adenosine deaminases acting on RNA (ADARs) and of the editing profile of phospho-diesterase 8A (PDE8A) Studying ADARs expression and RNA editing of genes associated with SB, including PDE8A and comparison of these results between healthy controls and depressed patients with or without history of SB At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression of ADAR1a enzymes Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of Spindle And Kinetochore Associated protein 2 (SKA2) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression of ADAR1b enzymes Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression of ADAR2 enzymes Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of Spermidine/Spermine N1-Acetyltransferase 1 (SAT1) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of Interleukins (ILs) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of Chemokines (CXCLs) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of Brain derived Neurotrphic factor (BDNF) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of Cluster of differentiation 24 (CD24) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of Three prime repair exonuclease 1 (TREX1) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of Interferon stimulated gene 15 (ISG15) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of Tumor necrosis factor alpha (TNF alpha) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of Vascular endothelial growth factor (VEGF) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of Hydroxytryptamine receptor 2A (HTR2A) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Modification of the expression and RNA editing of insulin-like growth factor protein 7 (IGFB7) Comparison between non suicidal and suicidal depressed patients and healthy controls At the inclusion visit, 3 months and 6 months after the inclusion
See also
  Status Clinical Trial Phase
Completed NCT03062150 - Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression N/A
Completed NCT04352101 - Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits Phase 4
Recruiting NCT03039387 - Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients N/A
Recruiting NCT02213016 - Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Phase 4
Completed NCT01683539 - Understanding How Cognitive Remediation Works N/A
Completed NCT01636791 - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Phase 3
Recruiting NCT02237937 - Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Phase 4
Completed NCT01201148 - Open Pilot Trial of TES for Depression Phase 2
Completed NCT00953108 - Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients Phase 3
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Terminated NCT01244711 - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines Phase 4
Completed NCT00806143 - Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression Phase 4
Terminated NCT00695552 - The Effect of Exercise on Depressive Symptoms in Unmedicated Patients N/A
Completed NCT00532480 - Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine Phase 4
Completed NCT00482482 - Yoga in Unipolar and Bipolar Disorders N/A
Completed NCT00466323 - The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness. N/A
Completed NCT00616759 - The Effect on Cognition of Terminating ECT Induced Seizures With Propofol N/A
Recruiting NCT00209807 - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Phase 4
Completed NCT00149110 - Chronos: the Use of Chronobiological Treatment in Depression N/A
Completed NCT00167310 - Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation Phase 2